COMPASS Pathways plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kabir Kumar Nath
- Full Time Employees
- 156
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 33 Broadwick Street London CH United Kingdom W1F 0DQ
- IPO Date
- Sep 18, 2020
- CIK
- 0001816590
- Website
- compasspathways.com
- Similar Companies
- Business
- COMPASS Pathways plc is a biotechnology company focused on developing innovative mental health treatments, primarily by advancing the potential of psychedelics as medicines. The company’s main product is COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation designed for the treatment of mental health disorders. COMP360 is in advanced clinical development, including Phase III trials for treatment-resistant depression (TRD) and Phase II studies for conditions such as post-traumatic stress disorder (PTSD) and anorexia nervosa. The company also engages in research collaborations and development of scalable delivery models for its therapies. COMPASS Pathways operates primarily in the United Kingdom and the United States, with its headquarters located in London, UK. Founded in 2020, the company went public under the ticker CMPS and has positioned itself as a pioneer in evidence-based psychedelic mental health innovation. Recent developments include several strategic research collaboration agreements to optimize clinical delivery models for COMP360 if approved by regulators. Notably, in early 2024, COMPASS Pathways entered into a three-year research collaboration with Greenbrook TMS, a leading provider of transcranial magnetic stimulation services in the U.S., aiming to create scalable, cost-effective treatment delivery frameworks. In addition, a research partnership with Hackensack Meridian Health was established to develop clinical models for COMP360. The company has been advancing clinical trials and expanding indications for COMP360 beyond depression, focusing on mental health conditions with unmet therapeutic needs. It has also secured additional funding rounds to support ongoing research and development activities and continues to explore strategic partnerships to facilitate commercialization efforts and broaden patient access to its investigational treatments. COMPASS Pathways does not currently operate any owned manufacturing facilities but relies on contract manufacturing for drug production. Its business segments include clinical development, regulatory affairs, and commercialization readiness for its psychedelic therapy platform. The company targets patients with serious mental health disorders unresponsive to existing treatments, healthcare providers, and mental health clinics in markets across North America and Europe. The company’s innovative focus and recent operational activities position it as a notable player in the emerging psychedelic pharmaceutical industry, blending advanced biopharmaceutical development with strategic collaborations to accelerate mental health treatment solutions. COMPASS Pathways was formerly known as COMPASS Rx Limited before changing to its current name in 2020. Its pipeline and strategic orientation remain focused on advancing COMP360 through late-stage clinical development and preparing for potential regulatory approvals and market launches. This description reflects the company’s current business activities, core product offerings, and latest strategic developments as of 2025, based on the latest available information from its official communication and financial disclosures.
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
CleanSpark shares surge after company secures $6.6B data center lease agreement
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways Elects Kathleen Tregoning to Board of Directors
Compass Pathways: A Trip Worth Taking Before The FDA Verdict
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Compass Pathways: Imminent Commercialization Should Provide Further Upside
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026